uniQure Target of Unusually Large Options Trading (NASDAQ:QURE)

[view original post]

uniQure (NASDAQ:QURE) saw some unusual options trading on Friday. Stock traders acquired 5,496 call options on the stock. This is an increase of approximately 929% compared to the typical daily volume of 534 call options.

In other uniQure news, CEO Matthew C. Kapusta sold 10,901 shares of uniQure stock in a transaction dated Wednesday, January 26th. The stock was sold at an average price of $18.10, for a total transaction of $197,308.10. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Alexander Edward Kuta III sold 6,000 shares of uniQure stock in a transaction dated Monday, November 15th. The shares were sold at an average price of $31.81, for a total value of $190,860.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 32,157 shares of company stock worth $722,636. Company insiders own 2.66% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the business. First Horizon Advisors Inc. increased its position in uniQure by 489.2% in the 3rd quarter. First Horizon Advisors Inc. now owns 383 shares of the biotechnology company’s stock worth $38,000 after buying an additional 318 shares during the period. Dark Forest Capital Management LP bought a new stake in shares of uniQure during the second quarter valued at approximately $27,000. Rockefeller Capital Management L.P. bought a new stake in shares of uniQure during the third quarter valued at approximately $41,000. First Quadrant L P CA bought a new stake in shares of uniQure during the fourth quarter valued at approximately $37,000. Finally, Future Financial Wealth Managment LLC bought a new stake in shares of uniQure during the fourth quarter valued at approximately $43,000. 78.95% of the stock is currently owned by institutional investors.

Shares of NASDAQ QURE opened at $16.83 on Friday. The company has a quick ratio of 14.17, a current ratio of 14.16 and a debt-to-equity ratio of 0.12. The business’s 50 day moving average is $20.76 and its two-hundred day moving average is $27.31. The company has a market cap of $777.78 million, a P/E ratio of 2.48 and a beta of 1.01. uniQure has a 12 month low of $15.89 and a 12 month high of $38.80.

Several equities research analysts have recently issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of uniQure in a report on Tuesday, October 26th. StockNews.com upgraded uniQure from a “sell” rating to a “hold” rating in a report on Saturday, February 5th. Zacks Investment Research lowered uniQure from a “buy” rating to a “hold” rating in a report on Thursday. William Blair assumed coverage on uniQure in a report on Wednesday, October 27th. They set an “outperform” rating and a $66.00 price target for the company. Finally, Raymond James lowered uniQure from a “strong-buy” rating to an “outperform” rating and reduced their price target for the company from $75.00 to $58.00 in a report on Thursday, December 16th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, uniQure has a consensus rating of “Buy” and an average target price of $55.38.

uniQure Company Profile

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

Featured Stories

Want More Great Investing Ideas?